Targeting GM-CSF in rheumatological conditions: risk of PAP - Authors' reply.

MLA

Genovese, Mark C., et al. “Targeting GM-CSF in Rheumatological Conditions: Risk of PAP - Authors’ Reply.” The Lancet. Rheumatology, vol. 3, no. 7, July 2021, pp. e473–74. EBSCOhost, https://doi.org/10.1016/S2665-9913(21)00146-6.

APA

Genovese, M. C., Buckley, C. D., Saurigny, D., Schett, G., Davy, K., Gupta, A., Smith, J. E., Patel, J., & Tak, P. P. (2021). Targeting GM-CSF in rheumatological conditions: risk of PAP - Authors’ reply. The Lancet. Rheumatology, 3(7), e473–e474. https://doi.org/10.1016/S2665-9913(21)00146-6

Chicago

Genovese, Mark C, Christopher D Buckley, Didier Saurigny, Georg Schett, Katherine Davy, Anubha Gupta, Julia E Smith, Jatin Patel, and Paul P Tak. 2021. “Targeting GM-CSF in Rheumatological Conditions: Risk of PAP - Authors’ Reply.” The Lancet. Rheumatology 3 (7): e473–74. doi:10.1016/S2665-9913(21)00146-6.